{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:44:45Z","timestamp":1779345885937,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We aim to elucidate the disease impact by accounting the prevalence, survival rate, genetics, mTOR inhibitor use and direct costs of tuberous sclerosis complex (TSC) in our local setting. TSC patients with documented visits to our local public hospitals in 1995\u20132018 were identified. The public hospitals captured most if not all local TSC patients. Demographics such as age, sex, death, genetic profiles were retrieved from the central electronic database. Data including prevalence, age distribution and survival rate were analysed. Direct cost was calculated with reference to the drug use and number of visits to various public hospital facilities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 284 surviving TSC patients (55.3% male) in Hong Kong. The age range was from 4.5\u2009months to 89.9\u2009years, with a median age of 27.2\u2009years. Paediatrics (&lt;\u200918\u2009years) to adult (\u226518\u2009years) ratio was 1:2.84. The overall prevalence of TSC patients was 3.87 in 100,000 (i.e. 1 in 25,833). Genetically, TSC1:TSC2 ratio is 1:2.7.<\/jats:p>\n                <jats:p>Thirty seven patients died within the study period. The age of death ranged from 7.6\u2009years to 77.8\u2009years, with a median age of death at 36.6\u2009years (IQR: 24.7\u201351.1\u2009years). Most patients survived till adulthood. Survival rate at 20 and 50\u2009years follow-up was 98.6 and 79.5% respectively.<\/jats:p>\n                <jats:p>Two hundred and twenty nine TSC patients (71.3%) had neurological manifestations, sixteen patients (5.0%) had chronic kidney diseases and five patients (1.6%) had pulmonary lymphangioleiomyomatosis. Forty seven (16.5%) TSC patients were prescribed with mTOR inhibitors within the study period. Healthcare facility utilization was further analysed in the 2008\u20132018 cohort. In particular, the mean number of specialist out-patient clinic visits per patient-year was 9.23 per patient-year, which was 4.91 times more than that of local general population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Prevalence of local TSC patients is within the range of that reported in the literature. Local TSC patients have fair long term survival, but they require disproportionally high healthcare cost when compared with the general population, particularly in terms of outpatient (OP) visits. Although effective disease-modifying agent (i.e. mTOR inhibitor) is available, it was not widely used yet in Hong Kong despite the fact that Government approved and supported its use recently. Further research on quality of life and setting up a comprehensive patient registry are necessary for more accurate assessment of cost and benefit.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01517-2","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T15:03:47Z","timestamp":1601305427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prevalence, mortality and healthcare economic burden of tuberous sclerosis in Hong Kong: a population-based retrospective cohort study (1995\u20132018)"],"prefix":"10.1186","volume":"15","author":[{"given":"William Ching-Yuen","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine Lok-Wing","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy Chi-Ching","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred Hing-Sang","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godfrey Chi-Fung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"issue":"5327","key":"1517_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M van Slegtenhorst","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805\u20138.","journal-title":"Science."},{"issue":"7","key":"1517_CR2","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"European Chromosome 16 Tuberous Sclerosis C","year":"1993","unstructured":"European Chromosome 16 Tuberous Sclerosis C. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305\u201315.","journal-title":"Cell"},{"issue":"9639","key":"1517_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657\u201368.","journal-title":"Lancet"},{"key":"1517_CR4","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske EP, Jozwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl","key":"1517_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0387-7604(94)00130-8","volume":"17","author":"MR Gomez","year":"1995","unstructured":"Gomez MR. History of the tuberous sclerosis complex. Brain and Development. 1995;17(Suppl):55\u20137.","journal-title":"Brain and Development"},{"issue":"2","key":"1517_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s004390000348","volume":"107","author":"JP Cheadle","year":"2000","unstructured":"Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet. 2000;107(2):97\u2013114.","journal-title":"Hum Genet"},{"key":"1517_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/B978-0-444-52891-9.00038-5","volume":"111","author":"P Curatolo","year":"2013","unstructured":"Curatolo P, Maria BL. Tuberous sclerosis. Handb Clin Neurol. 2013;111:323\u201331.","journal-title":"Handb Clin Neurol"},{"issue":"7","key":"1517_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00431-001-0903-7","volume":"161","author":"N Langkau","year":"2002","unstructured":"Langkau N, Martin N, Brandt R, Zugge K, Quast S, Wiegele G, et al. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1\/ TSC2 frequency ratios. Eur J Pediatr. 2002;161(7):393\u2013402.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"1517_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64\u201380.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"1517_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/epi.12680","volume":"55","author":"SV Kothare","year":"2014","unstructured":"Kothare SV, Singh K, Chalifoux JR, Staley BA, Weiner HL, Menzer K, et al. Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia. 2014;55(7):1025\u20139.","journal-title":"Epilepsia."},{"issue":"7","key":"1517_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1542\/hpeds.2016-0175","volume":"7","author":"J Jones","year":"2017","unstructured":"Jones J, Nowacki AS, Greene A, Traul C, Goldfarb J. Investigating parent needs, participation, and psychological distress in the Children's hospital. Hosp Pediatr. 2017;7(7):385\u201394.","journal-title":"Hosp Pediatr"},{"issue":"6","key":"1517_CR12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/dmcn.13352","volume":"59","author":"S Amin","year":"2017","unstructured":"Amin S, Lux A, Calder N, Laugharne M, Osborne J, O'callaghan F. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol. 2017;59(6):612\u20137.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"1517_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/157015912804499537","volume":"10","author":"P Curatolo","year":"2012","unstructured":"Curatolo P, Moavero R. mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol. 2012;10(4):404\u201315.","journal-title":"Curr Neuropharmacol"},{"issue":"12","key":"1517_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/acn3.494","volume":"4","author":"DA Krueger","year":"2017","unstructured":"Krueger DA, Sadhwani A, Byars AW, de Vries PJ, Franz DN, Whittemore VH, et al. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. Ann Clin Transl Neurol. 2017;4(12):877\u201387.","journal-title":"Ann Clin Transl Neurol"},{"key":"1517_CR15","unstructured":"Novartis Pharmaceuticals Corporation. Afinitor\u00ae (everolimus tablets for oral administration):\u00a0US prescribing information. Retrieved 17 July 2020, from http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/afinitor.pdf."},{"key":"1517_CR16","unstructured":"European Medicines Agency. Votubia\u00ae (everolimus): summary of product characteristics. Retrieved 17 July 2020, from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/votubia-epar-product-information_en.pdf."},{"key":"1517_CR17","doi-asserted-by":"publisher","unstructured":"Xu KF, Tian X, Ryu JH. Recent advances in the management of lymphangioleiomyomatosis.\u00a0F1000Res. 2018;7:F1000 Faculty Rev-758. https:\/\/doi.org\/10.12688\/f1000research.14564.1.","DOI":"10.12688\/f1000research.14564.1"},{"issue":"2","key":"1517_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"12","key":"1517_CR19","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071\u201381.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1517_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, d'Augeres GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):2.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1517_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1017\/S0012162206001058","volume":"48","author":"LA Devlin","year":"2006","unstructured":"Devlin LA, Shepherd CH, Crawford H, Morrison PJ. Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev Med Child Neurol. 2006;48(6):495\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"1517_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000254569","volume":"33","author":"CH Hong","year":"2009","unstructured":"Hong CH, Darling TN, Lee CH. Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study. Neuroepidemiology. 2009;33(4):335\u201341.","journal-title":"Neuroepidemiology."},{"issue":"2","key":"1517_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1378\/chest.14-3095","volume":"148","author":"AS Kristof","year":"2015","unstructured":"Kristof AS, Zhi Li P, Major P, Landry JS. Lymphangioleiomyomatosis and tuberous sclerosis complex in Quebec: prevalence and health-care utilization. Chest. 2015;148(2):444\u20139.","journal-title":"Chest"},{"issue":"6","key":"1517_CR24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/bjd.14415","volume":"174","author":"CH Hong","year":"2016","unstructured":"Hong CH, Tu HP, Lin JR, Lee CH. An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010). Br J Dermatol. 2016;174(6):1282\u20139.","journal-title":"Br J Dermatol"},{"key":"1517_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.seizure.2017.10.005","volume":"53","author":"KO Welin","year":"2017","unstructured":"Welin KO, Carlqvist P, Svensson A, Althin R, Eklund E, Rask O. Epilepsy in tuberous sclerosis patients in Sweden - healthcare utilization, treatment, morbidity, and mortality using national register data. Seizure. 2017;53:4\u20139.","journal-title":"Seizure"},{"issue":"1","key":"1517_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13023-019-1258-3","volume":"15","author":"JP Zollner","year":"2020","unstructured":"Zollner JP, Franz DN, Hertzberg C, Nabbout R, Rosenow F, Sauter M, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15(1):23.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1517_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1749-6632.1991.tb37786.x","volume":"615","author":"CW SHEPHERD","year":"1991","unstructured":"SHEPHERD CW, GOMEZ MR. Mortality in the Mayo Clinic tuberous sclerosis complex study. Ann N Y Acad Sci. 1991;615(1):375\u20137.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"1517_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","volume":"66","author":"CW Shepherd","year":"1991","unstructured":"Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991;66(8):792\u20136.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1517_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.pediatrneurol.2014.11.013","volume":"52","author":"AM Rentz","year":"2015","unstructured":"Rentz AM, Skalicky AM, Liu Z, Wheless JW, Dunn DW, Frost MD, et al. Tuberous sclerosis complex: a survey of health care resource use and health burden. Pediatr Neurol. 2015;52(4):435\u201341.","journal-title":"Pediatr Neurol"},{"issue":"8","key":"1517_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1185\/03007995.2011.586687","volume":"27","author":"L Hallett","year":"2011","unstructured":"Hallett L, Foster T, Liu Z, Blieden M, Valentim J. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin. 2011;27(8):1571\u201383.","journal-title":"Curr Med Res Opin"},{"key":"1517_CR31","unstructured":"Authority HKH. Hospital Authority statistical report 2016-2017. http:\/\/www3.ha.org.hk\/data\/HAStatistics\/DownloadReport\/2. (Accessed 18 January 2020)."},{"issue":"4","key":"1517_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA. International tuberous sclerosis complex consensus G. tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"key":"1517_CR33","unstructured":"Department HCaS. Hong Kong Annual Digest of Statistics. https:\/\/www.censtatdgovhk\/. (Accessed 18 January 2020)."},{"key":"1517_CR34","unstructured":"Authority HKH. Hospital Authority annual report 2018-2019. https:\/\/www.haorghk\/ho\/corpcomm\/AR201819\/PDF\/HA_Annual_Report_2018-2019pdf. (Accessed 18 January 2020)."},{"issue":"43","key":"1517_CR35","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.3748\/wjg.v23.i43.7716","volume":"23","author":"KS Cheung","year":"2017","unstructured":"Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. Epidemiology and natural history of Wilson's disease in the Chinese: a territory-based study in Hong Kong between 2000 and 2016. World J Gastroenterol. 2017;23(43):7716\u201326.","journal-title":"World J Gastroenterol"},{"issue":"26","key":"1517_CR36","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa020546","volume":"347","author":"SS Chiu","year":"2002","unstructured":"Chiu SS, Lau YL, Chan KH, Wong WH, Peiris JS. Influenza-related hospitalizations among children in Hong Kong. N Engl J Med. 2002;347(26):2097\u2013103.","journal-title":"N Engl J Med"},{"issue":"5","key":"1517_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/gim.2016.143","volume":"19","author":"CE Walker","year":"2017","unstructured":"Walker CE, Mahede T, Davis G, Miller LJ, Girschik J, Brameld K, et al. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort. Genet Med. 2017;19(5):546\u201352.","journal-title":"Genet Med"},{"issue":"1","key":"1517_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13023-018-0892-5","volume":"13","author":"ATG Chiu","year":"2018","unstructured":"Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong - adopting ORPHAcodes in ICD-10 based healthcare administrative datasets. Orphanet J Rare Dis. 2018;13(1):147.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"1517_CR39","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/13696998.2016.1199432","volume":"19","author":"JC Kingswood","year":"2016","unstructured":"Kingswood JC, Crawford P, Johnson SR, Sampson JR, Shepherd C, Demuth D, et al. The economic burden of tuberous sclerosis complex in the UK: a retrospective cohort study in the clinical practice research Datalink. J Med Econ. 2016;19(11):1087\u201398.","journal-title":"J Med Econ"},{"issue":"1","key":"1517_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13023-019-1072-y","volume":"14","author":"S Auvin","year":"2019","unstructured":"Auvin S, Bissler JJ, Cottin V, Fujimoto A, Hofbauer GFL, Jansen AC, et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet J Rare Dis. 2019;14(1):91.","journal-title":"Orphanet J Rare Dis."},{"key":"1517_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.yebeh.2019.04.027","volume":"96","author":"C Bar","year":"2019","unstructured":"Bar C, Ghobeira R, Azzi R, Ville D, Riquet A, Touraine R, et al. Experience of follow-up, quality of life, and transition from pediatric to adult healthcare of patients with tuberous sclerosis complex. Epilepsy Behav. 2019;96:23\u20137.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"1517_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","volume":"13","author":"O Sancak","year":"2005","unstructured":"Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet. 2005;13(6):731\u201341.","journal-title":"Eur J Hum Genet"},{"key":"1517_CR43","unstructured":"Authority HKH. Self-financed Drugs Available for Purchase by Patients at HA Pharmacies. http:\/\/www.haorghk\/hadf\/en-us\/Updated-HA-Drug-Formulary\/List-of-Self-financed-Items-to-be-sold-via-HA-pharmacies. (Accessed 18 January 2020)."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01517-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01517-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01517-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T23:45:57Z","timestamp":1632527157000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01517-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01517-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Institutional Review Board, The University of Hong Kong and West Cluster of Hospital Authority, Hong Kong.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}